Manuel Requena Shares The Results of the RESISTANT International Registry
Manuel Requena, Interventional Neurologist at Vall d’Hebron Barcelona Hospital Campus, shared in LinkedIn:
”I am pleased to share the results of the RESISTANT International Registry, recently published in Stroke: Vascular and Interventional Neurology, evaluating intracranial stenting during acute endovascular therapy for ischemic stroke.
I am deeply grateful to all the investigators, interventional teams, and stroke centers worldwide whose collaboration, commitment, and expertise made the RESISTANT registry possible.
This study reflects the power of international collaboration in advancing stroke care.
Together, we collected the largest cohort of patients who underwent acute intracranial stenting (876 patients across 36 international centers).
Key findings:
1. Acute intracranial stenting proved feasible and effective, achieving successful reperfusion (eTICI 2b–3) in nearly 90% of cases.
2. 41% of patients achieved good functional outcomes (mRS 0–2) at 90 days, despite the complexity of these challenging scenarios.
3. Final successful reperfusion and a lower number of thrombectomy attempts before stenting were the strongest predictors of favorable outcomes.
4. Reocclusion occurred in a minority of cases, mostly within the first 48 hours, and no independent predictors of symptomatic intracranial hemorrhage were identified.
Some substudies will be published very soon and we are working on new ones.”
Read the full article here.
Article: Intracranial Stenting During Acute Endovascular Therapy of Stroke: Clinical and Radiological Outcomes of the RESISTANT International Registry
Authors: Manuel Requena, Marta Olivé-Gadea, Francesco Diana, Johannes Kaesmacher, Adnan Mujanovic, Serdar Geyik, Songul Senadim, Alejandro Tomasello
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk
-
Sep 9, 2026, 15:39Alessandro Lucchesi: The Future of MPN Disease Modification
-
Sep 9, 2026, 15:10Pablo Corral: Is the Lp(a) Hypothesis Wrong?
-
Sep 9, 2026, 14:54Agnes Kisakye: Expanding Point-of-Care Ultrasound and Surgical Interventions for Hemophilia in Uganda
-
Sep 9, 2026, 14:52Jan Sloves: Addressing Diagnostic and Treatment Variability in Pelvic-Origin Varicose Veins
-
Sep 9, 2026, 14:48The French Care Pathway for Gene Therapy in Haemophilia B – CRH French Reference Center for Hemophilia Lyon
-
Sep 9, 2026, 14:43David McIntosh: The Ethics of Plasma Donation